28 September, 2018
“Biologics are one of the fastest-growing therapies in the world, yet 80% are still formulated as liquids—so they’re extremely costly to transport. We have a solution”, Ziccum CEO Göran Conradson is presenting to investors in Stockholm, Gothenburg and Malmö on the Ziccum investment case: formulating vaccines and biologics from liquids…
19 September, 2018
STOCKHOLM, SVERIGE – 19 september, 2018. Ziccum AB (publ) (“Ziccum”) har sedan tidigare godkänts för notering på Spotlight förutsatt att lägsta gränsen i bolagets nyemission samt marknadsplatsens ägarspridningskrav uppnås. Teckningstiden för bolagets nyemission inleds idag och pågår till och med den 3 oktober 2018. Första handelsdag på Spotlight är planerad…
19 September, 2018
STOCKHOLM, SWEDEN – 19 September, 2018. Ziccum AB (publ) has already been approved for listing on Stockholm stock market Spotlight, provided the minimum limit of the company’s new issue and the marketplace’s proprietary spread requirements are met. The subscription period for the company’s new share issue begins today and continue…
11 July, 2018
CEO Göran Conradson: "We’re well aware of how tough competition is for this funding, and how extensively applications are reviewed and evaluated. All projects selected in Horizon 2020 are seen as ground-breaking in their own way. We’re really proud and happy to be chosen."
18 May, 2018
Ziccum AB’s new Board of Directors includes the Head of Life Science at Chalmers Ventures, and a Senior Advisor at Karolinska Institutet Innovation AB. “The business and scientific calibre of our new members is a powerful vote of confidence in our product, market and vision,” says Ziccum CEO Göran Conradson.
9 April, 2018
On March 15 Inhalation Sciences submitted an update of its listing plans for Ziccum AB, providing further clarification on many of the questions it received at the company presentation at Erik Penser Bank. Here, Ziccum Chairman and ISAB CEO Fredrik Sjövall answers everything you may need to know on the upcoming listing of Ziccum AB.
19 March, 2018
On Wednesday 21 March Ziccum and ISAB CSO Per Gerde presents at the 'New Updates in Drug Formulation & Bioavailability' Conference in Copenhagen. Dr Gerde will speak on Ziccum's flagship spray drying tool LaminarPace.
15 March, 2018
Inhalation Sciences has updated its listing plans for Ziccum AB including schedule and a new preliminary valuation.
23 February, 2018
For the first time Ziccum CEO Göran Conradsson presents the story of LaminarPace to investors and analysts at Stockholm's prestigious Erik Penser Bank, Stockholm, March 15, 1200. But book early. Seats are limited.
20 February, 2018
Approx. 450 human antibodies are currently being developed to treat a wide range of diseases—but many are formulated as liquids, risking instability and attrition in clinical trials. Ziccum AB now releases full data from its recent proof-of-concept test showing how LaminarPace dries human antibodies into stable, active dry powders. The data include SEM (Scanning Electron Microscope) images, and more.